{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:17:16Z","timestamp":1763018236787,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bbmt.2020.08.014","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T22:30:14Z","timestamp":1597789814000},"page":"2299-2305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas"],"prefix":"10.1016","volume":"26","author":[{"given":"Catalina","family":"Montes de Oca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"De Philippis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Marc","family":"Schiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pagliardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Collignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Harbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Maisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Furst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faezeah","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bbmt.2020.08.014_bib0001","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.bbmt.2020.08.014_bib0002","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.bbmt.2020.08.014_bib0003","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bbmt.2020.08.014_bib0004","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bbmt.2020.08.014_bib0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bbmt.2020.08.014_bib0006","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bbmt.2019.05.014","article-title":"Thiotepa, fludarabine, and busulfan conditioning regimen before T cell-replete haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia: a bicentric experience of 100 patients","volume":"25","author":"Pagliardini","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 2)","key":"10.1016\/j.bbmt.2020.08.014_bib0007","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/bmt.2015.93","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update","volume":"50(","author":"Bacigalupo","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bbmt.2020.08.014_bib0008","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.bbmt.2014.06.006","article-title":"Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation","volume":"20","author":"Devillier","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.bbmt.2020.08.014_bib0009","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research Analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.bbmt.2020.08.014_bib0010","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bbmt.2020.08.014_bib0011","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bbmt.2020.08.014_bib0012","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/bmt.2016.348","article-title":"Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma","volume":"52","author":"Castagna","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bbmt.2020.08.014_bib0013","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/bmt.2015.79","article-title":"Familial haploidentical challenging unrelated donor allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available","volume":"50","author":"Garciaz","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"27","key":"10.1016\/j.bbmt.2020.08.014_bib0014","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.bbmt.2020.08.014_bib0015","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbmt.2020.08.014_bib0016","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bbmt.2020.08.014_bib0017","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bbmt.2020.08.014_bib0018","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.bbmt.2019.05.017","article-title":"Peripheral blood stem cells versus bone marrow for T cell-replete haploidentical transplantation with post-transplant cyclophosphamide in Hodgkin lymphoma","volume":"25","author":"Mariotti","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2020.08.014_bib0019","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.bbmt.2020.08.014_bib0020","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bbmt.2020.08.014_bib0021","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/cncr.31228","article-title":"Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide","volume":"124","author":"Ruggeri","year":"2018","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bbmt.2020.08.014_bib0022","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/s41409-019-0500-x","article-title":"Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients","volume":"54","author":"Granata","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bbmt.2020.08.014_bib0023","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bbmt.2020.08.014_bib0024","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bbmt.2020.08.014_bib0025","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bbmt.2020.08.014_bib0026","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2018018531","article-title":"Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.bbmt.2020.08.014_bib0027","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.19.02408","article-title":"Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR","volume":"38","author":"Fatobene","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.bbmt.2020.08.014_bib0028","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.bbmt.2020.08.014_bib0029","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bbmt.2020.08.014_bib0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bbmt.2020.08.014_bib0031","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","article-title":"Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation?","volume":"26","author":"Dreger","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bbmt.2020.08.014_bib0032","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bbmt.2020.08.014_bib0033","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/tid.12455","article-title":"Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients","volume":"17","author":"Ruggeri","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1016\/j.bbmt.2020.08.014_bib0034","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bbmt.2018.12.142","article-title":"Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation","volume":"25","author":"Copelan","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"2","key":"10.1016\/j.bbmt.2020.08.014_bib0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/tid.12365","article-title":"Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis","volume":"17","author":"Crocchiolo","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.bbmt.2020.08.014_bib0036","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/bjh.16189","article-title":"Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation","volume":"187","author":"Mohty","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120305061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120305061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:14:07Z","timestamp":1761059647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120305061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1083879120305061"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.014","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}